• Effects of an individualized prescriptive exercise intervention [ Designated as safety issue: No ]
  

• Feasibility of developing an individualized prescriptive exercise program [ Designated as safety issue: No ]
  
• Changes in cardiovascular endurance, muscular strength, and selected blood parameters [ Designated as safety issue: No ]
  
• Response of inflammatory proteins to exercise [ Designated as safety issue: No ]
  
• Fatigue, depression, and quality of life [ Designated as safety issue: No ]
  

OBJECTIVES:

Primary

• Determine the effects, in terms of fitness and blood parameters, fatigue levels, and quality of life, of an individualized prescriptive exercise intervention in patients with newly diagnosed acute or relapsed myeloid or lymphoblastic leukemia undergoing chemotherapy.

Secondary

• Determine the feasibility of developing an exercise program for these patients.
• Assess the changes in cardiovascular endurance, muscular strength, selected blood parameters, and response of inflammatory proteins to exercise in these patients.
• Evaluate fatigue, depression, and quality of life of these patients.

OUTLINE: This is a pilot study.

Patients participate in an individualized prescriptive exercise intervention 3 to 4 times per week for 6 weeks (4 weeks in hospital, 2 weeks at home). Exercise begins concurrently with the first course (induction therapy) of chemotherapy. Each exercise session consist of 3-5 minutes of light stretching (stretching component), 5-10 minutes of cycling on the recumbent bicycle (cardiorespiratory component), 5-15 minutes of resistance training including hand dumbbells, exercise tubing, rubber bands, and fit balls (resistance training component), and 5-10 minutes of abdominal exercises (core muscles component).

Quality of life, fatigue, and depression are assessed at baseline and weekly during study intervention.

Blood samples are collected at baseline and at weeks 3 and 6 for cytokine analysis.

DISEASE CHARACTERISTICS:

• Newly diagnosed acute or relapsed myeloid or lymphoblastic leukemia

  • Currently receiving re-induction therapy or designated for chemotherapy treatment
• Expected hospital stay of 3-4 weeks or longer
• Participation in the study must be approved by the physician directly responsible for the patient's care while at University of North Carolina Hospitals

PATIENT CHARACTERISTICS:

• No condition that would compromise the patient's ability to participate in the exercise rehabilitation program, including any of the following:

  • Immune deficiency
  • Acute or chronic bone, joint, or muscular abnormalities
  • Acute or chronic respiratory disease
  • Cardiovascular disease

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics